文献速递泌尿生殖技术与安全PETMR

68Ga-PSMA PET/MRI 诊断原发性及生化复发前列腺癌的 Meta 分析

68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis.
PubMed 文献 · Eur J Radiol · 2020-06-20

该 Meta 分析纳入 13 项研究共 707 例患者,评估 68Ga-PSMA PET/MRI 对原发性前列腺癌和生化复发的诊断效能。原发性前列腺癌合并敏感度 0.83(95%CI 0.73-0.90)、特异度 0.81(95%CI 0.61-0.93);生化复发合并检出率 76%(95%CI 72%-79%),且检出率随 PSA 水平升高而升高。

要点

  • 68Ga-PSMA PET/MRI 诊断原发性前列腺癌合并敏感度 0.83、特异度 0.81。
  • 生化复发合并检出率 76%,PSA 0-0.2、0.2-1、1-2、>2 ng/mL 分别为 38%、67%、74%、95%。
  • 检出率与 PSA 水平正相关,但研究间存在显著异质性。

核心结论

  • 68Ga-PSMA PET/MRI 可能是诊断原发性前列腺癌的有效影像方法,对生化复发患者诊断准确率也较高,且与 PSA 水平正相关。

研究设计与样本

  • Meta 分析,检索 PubMed、EMBASE、Cochrane Library 和 Web of Science 至 2019 年 9 月 12 日,纳入 13 项研究共 707 例患者,采用 QUADAS-2 工具评价质量,随机效应模型合并敏感度、特异度和检出率。

诊断标准与关键数值

  • 原发性前列腺癌:合并敏感度 0.83(95%CI 0.73-0.90),合并特异度 0.81(95%CI 0.61-0.93)。生化复发:合并检出率 76%(95%CI 72%-79%);PSA 0-0.2 ng/mL 组 38%,0.2-1 ng/mL 组 67%,1-2 ng/mL 组 74%,>2 ng/mL 组 95%。

临床应用与阅片要点

  • 作者认为 68Ga-PSMA PET/MRI 可能是诊断原发性前列腺癌的有效影像方法,对生化复发诊断准确率也较高,且与 PSA 水平正相关。

局限性

  • 研究间存在显著异质性。
  • 原文报告无明显发表偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Our meta-analysis aimed to evaluate the diagnostic performance of 68Ga-labelled prostate-specific membrane antigen ligand positron emission tomography/magnetic resonance imaging (68Ga-PSMA PET/MRI) in patients with primary and biochemically recurrent prostate cancer (PCa).

METHODS: We searched for relevant articles in PubMed, EMBASE, the Cochrane Library and Web of Science until September 12, 2019. Studies regarding the diagnostic performance of68Ga-PSMA PET/MRI in detecting primary PCa and biochemical recurrence (BCR) after definitive treatment were included. The quality of each study was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The pooled sensitivity and specificity of PET/MRI in identifying primary PCa and the pooled detection rate of PET/MRI for BCR were calculated using a random-effects model.

RESULTS: A total of 13 studies with 707 patients were included in the analysis, and the pooled sensitivity and specificity of PET/MRI in detecting primary PCa were 0.83 (95 % CI, 0.73-0.90) and 0.81 (95 % CI, 0.61-0.93), respectively. In the pooled analysis of BCR, the pooled detection rate was 76 % (95 % CI, 72 %-79 %). For four levels of PSA (0-0.2 ng/mL, 0.2-1 ng/mL, 1-2 ng/mL and more than 2 ng/mL), the pooled detection rates were 38 %, 67 %, 74 %, and 95 %, respectively. There was no distinct publication bias, but there was significant study heterogeneity.

CONCLUSIONS: 68Ga-PSMA PET/MRI is likely an effective imaging method in the diagnosis of primary PCa. In addition, the diagnostic accuracy of 68Ga-PSMA PET/MRI in patients with BCR was also high, positively correlating with PSA levels.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang R, Shen G, Yang R, et al. 68Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis. Eur J Radiol. 2020. PMID: 32622250. doi:10.1016/j.ejrad.2020.109131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。